Dimethylhexylamine (DMHA).
DMHA is a synthetic stimulant amine. It pushes noradrenaline out of nerve endings and slows its reuptake, which lifts alertness and raises heart rate and blood pressure.
- Category
- Compound
What Dimethylhexylamine (DMHA) is, and what it does.
- Does it work
- The audience here is narrow. Anyone competing under anti-doping rules will test positive, and United States regulators have said it doesn't meet the definition of a dietary ingredient.
- How much to take
- No daily amount is on record for DMHA and we won't invent one. Its clearance depends on urine pH, so the same amount lasts noticeably longer in some people than in others.
- Time to feel it
- Stimulant amines of this class come on within roughly half an hour to an hour of an oral dose, and how quickly it fades varies a lot between people.
- The first dose
- Day one is the whole story with a stimulant: alertness and a faster pulse that arrive quickly, then a fade that runs longer in some people than others.
- With regular use
- Repeated dosing brings tolerance, because a releasing agent draws down the pool it depends on. No long-term human trials on this compound exist to describe.
- How well tolerated
- Plain words: it raises heart rate and blood pressure, it sits on the World Anti-Doping Agency prohibited list, and several regulators have restricted it. Talk to a clinician first.
- How it feels
- Sharp, fast alertness with a physical edge. Raised pulse, sometimes a wired or jittery feeling, then a comedown as it clears.
- The overlooked benefit
- Two different molecules share the DMHA name, octodrine and 2-amino-6-methylheptane. They aren't the same thing, and only the label wording tells you which one is inside.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- noradrenaline release and subjective alertnessNarrative review
- rise in heart rate and blood pressureNarrative review
- claimed natural occurrence in walnut, aconite and kigeliaNarrative review
- pH-dependent renal clearanceNarrative review
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Both raise sympathetic tone, and the cardiovascular effects add rather than cancel. Pre-workout formulas routinely combine them, which stacks heart rate and blood pressure responses in the same session. Anyone with a cardiovascular history or on stimulant medication has a real reason to avoid the combination.
The anhydrous form is the same molecule delivered in a fast-dissolving powder, so the peak plasma rise is sharper. Layering that peak onto an aliphatic amine stimulant concentrates the cardiovascular load into a short window. Dose stacking across two products is the common way people arrive at more than they intended.
Yohimbine blocks presynaptic alpha-2 receptors, which removes the brake on noradrenaline release. Adding it to an amine stimulant amplifies the sympathetic response rather than complementing it. Anxiety, palpitations and blood pressure spikes are the reported consequences of this stack.
Higenamine is a beta-adrenergic agonist that appears in the same product category. Its cardiovascular effects run in the same direction as an amine stimulant. Both are prohibited in competition under anti-doping rules, so the stack carries a sanction risk on top of the physiological one.
Theanine blunts the subjective jitteriness of caffeine in controlled studies, and formulators extend that logic to other stimulants. There is no published work testing theanine against this particular amine. Smoothing how something feels does not lower the cardiovascular load it is producing.
Melatonin signals the onset of biological night while an adrenergic stimulant does the opposite. Taken close together they work against each other, and the practical result is usually a poor night's sleep despite the melatonin. Human pharmacokinetics for this amine have not been published, so how late in the day a dose still interferes is not established.
Sedative botanicals are frequently taken to undo the sleep disruption a stimulant caused earlier in the day. The two pull in opposite directions rather than balancing out. Layering a sedative onto residual stimulant is a pattern worth naming rather than recommending.
St John's wort has weak monoamine oxidase activity in laboratory work and strongly induces CYP3A4. Combining a monoamine-releasing agent with anything touching monoamine oxidase is a recognised pharmacological hazard. This one belongs on a caution list rather than a stack list.
Rhodiola extracts inhibit monoamine oxidase in in vitro assays, though whether that translates to a meaningful effect at supplement doses in people is unresolved. Pairing it with a monoamine releaser is a theoretical concern that has not been quantified. Read it as mechanistic rather than clinical.
Alkalinising the urine reduces the ionised fraction of a basic amine in the renal tubule and slows its clearance, which extends exposure. This is the same principle that governs other basic sympathomimetics. Anyone dosing bicarbonate for training buffering should know it can prolong a stimulant's stay.
Beta-alanine appears in nearly every pre-workout that has carried this amine, and its paraesthesia is often mistaken for the stimulant taking effect. The two have no shared mechanism. Naming that confusion matters because people use the tingle to judge whether a dose landed.
Nothing specific on file for Dimethylhexylamine (DMHA). Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Dimethylhexylamine (DMHA) actually does.
It is a synthetic stimulant molecule from the same chemical family as other lab-made amines. It is not a vitamin, mineral or plant nutrient.
Competitive athletes will fail a drug test on this.
Regulators in several countries have said it does not belong in a supplement at all.
How fast it leaves your system depends partly on urine pH, so duration varies person to person.
Where Dimethylhexylamine (DMHA) comes from.
It is made in a lab from a branched ketone. The plant names printed on the label are not where it comes from.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Routes start from a branched seven-carbon ketone such as 6-methyl-2-heptanone, or from an equivalent nitroalkane.
The carbonyl is converted to the primary amine by reductive amination with ammonia, or the nitro group is reduced. Both give a racemic mixture unless a chiral route is used.
The crude amine is converted to hydrochloride or citrate and recrystallised, which removes unreacted precursor and positional isomers to a variable degree.
Typically combined with caffeine and other stimulants. Independent testing of finished products has repeatedly found label amounts that do not match assay.
Isomer identity, actual amine content per capsule and true origin are routinely undeclared, and third-party assays of finished products have found stated and measured amounts diverging widely.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.